Octahydro phenanthridine derivatives useful as NMDA-R receptor subtype blockers

US6071929A · kind A · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• Alexander Alanine · Basel, CH
• Anne Bourson · Mulhouse, FR
• Bernd Buttelmann · Schopfheim, DE
• Gunther Fischer · Lörrach, DE
• Marie-Paule Heitz Neidhart · Rixheim, FR
• Vincent Mutel · Mulhouse, FR
• Emmanuel Pinard · Rixheim, FR
• Stephan Rover · Weil am Rhein, DE
• Gerhard Trube · Rheinfelden (Baden), DE
• Rene Wyler · Zürich, CH

Key dates

• Filing date: May 26, 1999
• Grant date: Jun 6, 2000
• Expiry date: May 26, 2019

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D221/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to the use of tetrahydroisoquinoline derivatives of the general formula: ##STR1## wherein: A is aryl PA1 R.sup.1 is hydrogen, hydroxy, lower alkyl, lower alkoxy, R--CO-- or R--COO--, wherein R is lower alkyl; PA1 R.sup.2 is hydrogen, lower alkyl or cycloalkyl PA1 R.sup.3 -R.sup.7 are independently hydrogen, lower alkyl, lower alkoxy, hydroxy or PA1 R.sup.3 and R.sup.4 taken together are --(CH.sub.2).sub.n -- or PA1 R.sup.6 and R.sup.7 taken together are --OCH.sub.2 O-- and PA1 n is 3 or 4, as well as pharmaceutically acceptable salts for the manufacture of medicaments for the control or treatment of diseases which represent therapeutic indications for NMDA receptor subtype specific blockers.